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ABSTRACT
Objective: This study was undertaken to evaluate the changes in total and anti-herpes simplex virus
(HSV)-specific cervical IgA and IgG antibody profiles during and after pregnancy.
Methods: Serum and cervical secretions were obtained from pregnant patients before 20 weeks
gestation, at 34-36 weeks gestation, and at 6 weeks postpartum and tested for total IgA and IgG
antibody and for IgA and IgG to HSV proteins by Western blot.
Results: Seven women were HSV seronegative, 14 HSV-1 seropositive, and 14 HSV-2 + HSV-
1 seropositive. Minimal changes in the serum anti-HSV profiles were seen over the 3 visits. The
total cervical IgA, IgG, and protein levels did not change between the 2 pregnancy visits but tended
to increase at the postpartum visit. No consistent change in cervical HSV-specific IgA and IgG
was seen during pregnancy, but the levels increased markedly at the postpartum visit.
Conclusions: Lower cervical anti-HSV antibody levels may be related to the previously reported
increased frequency ofa reactivation ofHSV during late pregnancy. Further evaluation is necessary
to confirm and quantify the changes in ,genital immunity during pregnancy and to evaluate whether
the increased levels at the postpartum’visit are sustained. (C) 1996 Wiley-Liss, Inc.
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enital herpes simplex virus (HSV) infections
are common among pregnant women, with up
to 40% having antibody to HSV-2.1-4The risk factors
for the perinatal transmission ofHSV include recent
primary genital infection, cervical rather than only
labial HSV shedding, use of fetal-scalp electrodes,
and lack of maternal antibody, particularly antibody
to an HSV-2 type-specific glycoprotein, gG.
5-9
Among some women with recurrent genital HSV
infections, reactivation increases in the third trimes-
ter,
1 which may result in a greater risk of perinatal
transmission. The factors responsible for the in-
creased rate of reactivation in late pregnancy have
not been elucidated, but may be associated with
the immunologic changes characteristic of late
pregnancy.TM
One possible contributor to the increased genital
HSV reactivation in late pregnancy is a change in
local antibody levels. In addition to serum antibody,
a genital HSV infection induces mucosal antibod-
ies,
3-9 which are directed against a number of viral
proteins, that are demonstrable months after the
infection and neutralize HSV in vitro. Although sys-
temic levels of immunoglobulins do not appear to
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change during pregnancy,z the effect of pregnancy
on mucosal antibodies has not been assessed. To
evaluate the effects of pregnancy on circulating and
local cervical total and anti-HSV-specific immuno-
globulins, we used quantitative assays to assess cer-
vical total IgA and IgG levels and semiquantitative
methods to analyze the HSV-specific IgA and IgG
in serum and cervical secretions collected during
the first halfofpregnancy, at 34-36 weeks gestation,
and at 6 weeks postpartum.
SUBJECTS AND METHODS
Study Population and Protocol
Pregnant women were enrolled in the study from
the prenatal clinics of the University ofWashington
Medical Center and Harborview Medical Center
between January 1991 and March 1992. All subjects
gave informed consents as approved by the Univer-
sity ofWashington Institutional Review Board. The
patients were enrolled before 20 weeks gestation
and were seen again at 34-36 weeks gestation and
6 weeks postpartum. Of the 55 patients who were
enrolled, 37 completed at least 2 visits. Of the 18
(33%) who did not complete the study, 13 were lost
to follow-up, moved from the area, and 4 were
removed for obstetric reasons (spontaneous abor-
tion in 3 and placenta previa in 1). All women had
blood drawn at entry (8-20 weeks) to determine
their HSV serologic statuses. Herpes viral cultures
of the labia and cervix were performed, and cervical
secretions were sampled at all visits. A brief ques-
tionnaire regarding current symptoms of a genital
or oral HSV infection was completed at each visit.
Viral cultures were performed as previously de-
scribed. The serum specimens were assayed for
IgA and IgG antibodies to HSV-1 and HSV-2 by
Western blot analyses, zl’zz
Cervical Secretions
The cervical secretions were obtained as previously
described. TM Briefly, a vaginal speculum was in-
serted and 2 ophthalmic tear-flow test strips ("Sno-
strip," Akorn, Inc., Abita Springs, LA) were placed
sequentially on the cervical os until they were satu-
rated to the shoulder, approximately 10 sec each.
This technique provided a constant volume of se-
cretions with each sample (mean volume
357 +__ 77 Il/sample). TM The combined papers from
a single sampling were trimmed at the shoulder,
and the saturated strips were then sealed in sterile
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vials containing 500 !1 of a 0.01 sodium azide
solution in phosphate-buffered saline (PBS) and
frozen at 20C.
Specimen Preparation
The samples were thawed. After the Sno-strips
were removed, the vials were vortexed, then centri-
fuged at 13,960 g for 15 min. The supernatant vol-
umes were recorded, and a 50-11 portion was re-
moved from each sample for protein analysis (Bio-
Rad, Richmond, CA) as previously described. TM The
samples were tested for occult blood by Hemoccult
(Smith-Kline Diagnostics, San Jose, CA), but the
positive samples were not analyzed.
Total Cervical IgG, IgA Determinations
Purified human IgA (Sigma, St. Louis, MO) and
human IgG standards (Pierce, Rockford, I1) were
serially diluted 2-fold to 1:10,000 and 1:80,000, re-
spectively, in carbonate buffer (pH 9.6) and dis-
pensed into 96-well plates. The secretions were
serially diluted 2-fold from 1:40 for IgA and from
1:200 for IgG into the same plates. Bound antibod-
ies were detected with peroxidase-conjugated goat
anti-human o chain or /chain (Tago, Burlingame,
CA) and 3,3 ’,5,5 ’-tetramethylbenzidin6 (TMB;
Kirkegard& Perry, Gaithersburg, MD). Absorbance
values at 450 nm were plotted for each dilution; 3
points were chosen from the linear parts of the IgA
and IgG standard curves and regression lines were
calculated. Two points were then chosen from the
linear part of the specimen curves within the range
of the regression lines, and IgA and IgG concentra-
tions in the cervical samples were extrapolated.
Enhanced Chemiluminescence
(ECL)-Western Blot
Western blots of polyvinylidine difluoride (Immob-
ilon, Millipore Corp., Bedford, MA) were prepared
as described previously
13 using HSV-2 or mocked-
infected extracts from conventional cultures of hu-
man diploid fibroblasts. The cervical secretions
were diluted 1:40 in a 4% solution of goat serum in
PBS, then incubated with blots at room temperature
overnight on a rocker platform. The blots were
washed 3 times with 0.5% Tween-20 in PBS and
once with PBS and incubated for 90 min at room
temperature with horseradish peroxidase-conju-
gated secretory antibody: goat anti-human IgA
chain diluted 1:10,000 in PBS; Pierce) or goat anti-HSV ANTIBODYIN PREGNANCY WATTS ET AL.
human IgG (/chain diluted 1:10,000 in PBS; Boeh-
ringer Mannheim Biochemicals, Indianapolis, IN).
After being thoroughly washed with PBS/
Tween, the blots were incubated for min with
a commercial Western blotting detection system
based on chemiluminescence as directed by the
manufacturer (Amersham, Arlington Heights, IL).
The blots were then covered with plastic wrap and
exposed to Hyperfilm-ECL (Amersham) for a range
of times: 10 sec to 3 min. The film was then devel-
oped in a Kodak X-Omat processor.
All specimens from each patient were tested
against the same lot of ECL-Western blot strips
and in the same immunoblot run. For an accurate
comparison of antibody profiles across time points,
each set of blots for HSV-specific IgA or IgG was
developed for the same length oftime. The changes
in relative levels of IgA or IgG to HSV were scored
if at least 3 major bands showed a marked difference
in intensity or if the bands were present in speci-
men and absent in the other specimens being com-
pared. The reactive bands were identified by migra-
tion characteristics as described previously,
zz,z3
Statistical Analysis
The median levels of protein and total IgG and IgA
from the cervix at each visit were compared using
the 2-tailed Wilcoxon’s signed-rank test. z4 The
changes scored as increased or decreased levels of
HSV-specific cervical IgA and IgG by ECL-West-
ern blot between visits were evaluated using a 2-
tailed sign test. z4
RESULTS
HSV Serostatus
Of the 37 patients who completed the study, 35
subjects had at least 2 cervical samples taken for
local antibody measurements that were Hemoccult
negative. Of these, 7 (20%)were HSV seronegative,
14 (40%) had antibodies to HSV-1, 10 (29%) had
antibodies to HSV-2, and 4 (11%) had antibodies
to both HSV-1 and HSV-2. In the following analy-
ses, the 4 patients with antibodies to both HSV-1
and HSV-2 were grouped with the 10 who had
antibodies to HSV-2 only.
Prenatal Cervical Protein, IgA, and IgG Levels
Thirty-five women had cervical specimens taken
during the third trimester for comparison with en-
rollment samples for total cervical protein concen-
trations, total IgA, and total IgG. The results ac-
cording to HSV serostatus are shown in Table 1.
No significant differences in median protein, total
IgA, or total IgG values were found between the
enrollment and third-trimester samples in seronega-
tive women or in HSV-1 or HSV-2 seropositive
women compared with HSV seronegative women.
Moreover, all values were similar between the 2
time points.
Postpartum Changes in Total Protein, Total
IgA, and IgG
Nineteen of35 (54%) women had evaluable cervical
specimen pairs from third-trimester and postpartum
visits (Table 1). Overall, the median values of total
protein, IgA, and IgG rose 3-fold to 5-fold in the
postpartum samples. This rise was especially ap-
parent in local IgA which rose from a median
of 1.32 to 6.3 meg/ml (P < 0.005). Of interest, this
rise was seen mainly in the HSV seronegative and
HSV-1 seropositive subsets. The median IgA values
rose approximately 10-fold in seronegative women
(P 0.08) and HSV-1 seropositive women (P
0.03) and by 2-fold in HSV-2 seropositive women
(P 0.35) (Table 1).
The specimen volume, our measure of adequacy
and uniformity of the sampling technique, showed
no significant change between the pre- and postpar-
tum samples (P 0.50, P 0.51, P 0.35, and
P 0.63 for HSV seronegative, HSV-1 seropositive,
HSV-2 seropositive, and all patients, respectively)
or between the HSV seronegative and HSV-1 vs.
HSV-2 seropositive specimens.
Enrollment and Third-Trimester Cervical
HSV-I IgA Profiles
Fourteen women who were seropositive for HSV-
had samples taken both at the enrollment visit
and during the third trimester for comparison of
HSV cervical antibody profiles. Of these sample
pairs, 3 had no detectable IgA to HSV-1 in either
sample. Of the 11 with detectable antibodies, 5 had
unchanging profiles of HSV-1 cervical IgA and 3
had increases and 3 had decreases in the number
and intensity of reactive bands on ECL-Wesetern
blot (Table 2). An example of the low prenatal
levels of cervical IgA to HSV is shown in Figure
1A (lanes and 2). Note that detectable cervical
IgG to HSV was present at all sampling points (Fig.
1B). The serum IgA (Fig. 1C) and IgG antibody
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TABLE I. Cervical protein, IgA, and IgG levels at each visit
HSV No. of Median protein Median IgA Median IgG
status patients Visit (range), Ig/lxl (range), Ixg/Ixl (range),
Negative 7 Enrollment 19 (5-53) 2.23 (0.12-5.54) 2.78 (0-23.31)
3rd trimester 40 (10-5 I) 1.32 (0-4.05) 2.41 (0-5.76)
P 0.35 P 0.18 P 0.50
5 3rd trimester 24 (10-5 I) 1.87 (0-4.05) 3.41 (0-3. I)
Postpartum 250 (30-308) 12.16 (0.05-45.15) 14.33 (0.03-21.34)
P 0.07 P 0.08 P 0.08
HSV-I only 14 Enrollment 22.5 (4-230) 1.87 (0.01-19.61) 3.31 (0.1-36.49)
3rd trimester 29 (10-134) 1.44 (0.01-7.26) 3.42 (0.16-18.42)
P 0.92 P 0.73 P 0.93
9 3rd trimester 29 (10-134) 1.59 (0.32-7.26) 3.35 (0.83-18.42)
Postpartum 62 (13-405) 10.86 (I.76-24.65) 10.5 (0.36-16.88)
P 0.14 P 0.03 P 0.17
HSV-2 14 Enrollment 25 (0-63) 1.83 (0.03-12.71) 4.14 (0.16-4 1.09)
3rd trimester 22.5 (0-484) 1.51 (0.03-10.12) 2.82 (0.252-33.79)
P 0.68 P 0.22 P 0.70
5 3rd trimester 34 (I I-I 14) 0.97 (0.22-7.56) 8.47 (I.17-53.79)
Postpartum 24 (15-90) 2.18 (0.27-9.59) 8.62 (3.65-19.08)
P 0.69 P 0.35 P 0.89
Total 35 Enrollment 21 (0-230) 1.93 (0.01-19.61) 3.49 (0-41.09)
3rd trimester 29 (0-484) 1.41 (0-10.12) 3.11 (0-33.79)
P 0.55 P 0. II P 0.49
19 3rd trimester 29 (10-134) 1.32 (0-7.56) 2.72 (0-33.79)
Postpartum 91 (I 3-405) 6.27 (0.05-45.15) 10.5 (0.03-31.34)
P 0.05 P < 0.005 P 0.08
aWilcoxon’s signed-rank test, 2-tailed P value comparing paired visits as indicated.
TABLE 2. Changes in ECL-Western blot cervical antibody profiles against HSV proteins between visits
HSV Cervical IgA
serologic No No
status change Increase Decrease Total change
Cervical IgG
Increase Decrease Total
Enrollment and 3rd trimester
HSV-I 5 (45%) 3 (27%) 3 (27%) II 7 (50%) 3 (21%) 4 (29%) 14
HSV-2 2 (20%) 2 (20%) 6 (60%) 10 4 (29%) 6 (42%) 4 (29%) 14
Total 7 (33%) 5 (24%) 9 (43%) 21 II (39%) 9 (32%) 8 (29%) 28
3rd trimester and postpartum
HSV-I 0 9 (90%) 1(10%) 10 1(10%) 8 (80%) 1(10%) 10
HSV-2 0 5 (83%) (17%) 6 0 4 (67%) 2 (33%) 6
Total 0 14 (88%) 2 (I 2%) 16" (6%) 12 (75%) 3 (I 9%) 16"*
aECL-Western blot profiles of cervical IgA and cervical IgG were compared between enrollment and 3rd-trimester blots and between 3rd-trimester
and postpartum blots, as illustrated in Figures and 2. Numbers in parentheses are the percentages of subjects with a given result within the population
of pairs scored ("Total"). Increase at least major bands on ECL-Western blot were markedly increased in intensity or were present in the second
but not the first blot of the pair. Decrease at least major bands on ECL-Western blot were markedly decreased in intensity or were present on
the first but not the second blot of the pair. All blots for the same subject were run at the same time under the same conditions for each antibody
type (IgA or IgG).
bDoes not include HSV-I seropositive and 4 HSV-2 seropositive women who either had no detectable IgA antibody to HSV in their samples or
<10 ng of protein in one or both samples.
*P 0.004 by 2-tailed sign test.
**P 0.08 by 2-tailed sign test.
profiles to HSV-1 (Fig. 1D) did not change over
time. No cervical IgA or IgG antibodies against
HSV-1 or HSV-2 proteins were detected at any of
the 3 visits in seronegative patients.
Five ofthe 6womenwho had apparent changes in
cervical IgA profiles had concordant changes (either
increases or decreases) in their total protein levels as
well. The volumes of the paired specimens in 5 of
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Fig. I. Cervical and serum antibody profiles from samples
obtained over time from an HSV-I seropositive patient.
ECL-Western blots were performed to detect cervical anti-
bodies to HSV-I (A,B) and serum antibodies to HSV-I
(C,D). The left blot in each panel is from specimens taken
at enrollment, the middle blot from specimens taken during
the third trimester, and the right blot from specimens taken
6 weeks postpartum. Note the dramatic increase in band
number and intensity in cervical IgA and IgG to HSV-I be-
tween the third-trimester and postpartum samples. In con-
trast, the serum profiles show no change in the IgA profile
to HSV-I over the 3 time points. The serum IgG profiles,
while difficult to read at this exposure because of the high
IgG, show evidence of a decrease in intensity in the third-
trimester serum and recovery of intensity in the postpar-
tum serum.
the 6 pairs with changes were either similar between
the pairs or showed discordant change, suggesting
that sampling differences alone were not sufficient
to explain the changes. The sixth pair had a lower
volume in the third-trimester sample along with de-
creasing apparent levels of IgA to HSV-1; however,
her IgG levels increased between the 2 specimens.
Ofnotewas that subjecthad labial blisters thatwere
culture positive for HSV-1 at the time of her third-
trimester sampling; her HSV-l-specific IgA in geni-
tal secretions decreased to undetectable levels at this
sampling. None of the other genital cultures ob-
tained were positive for HSV during the study.
Postpartum Cervical HSV-I IgA
Fourteen women with HSV-1 antibody had speci-
mens taken in the third trimester and at 6 weeks
postpartum. The postpartum samples from 4
women contained blood and could not be evaluated
for cervical antibody. Of the 10 available pairs, all
had demonstrable HSV-IgA in the postpartum cer-
vical secretions and 9 (90%) had clear increases in
cervical HSV-IgA profile complexity and intensity,
while 1 had a decrease (Table 2). Figure 1A (lane
3) gives an example of the increased intensity and
complexity of the IgA profile postpartum.
Enrollment and Third-Trimester Cervical
HSV-2 IgA Profiles
IgA to HSV-2 was compared in enrollment and
third-trimester samples of 14 women who were se-
ropositive for HSV-2. Of the 14 pairs, 4 lacked de-
tectable IgA. Of the 10 with detectable HSV-2 anti-
body, 2 had no change, 2 had increasing complexity
and intensity of profiles, and 6 had decreasing
amounts of antibodies in their cervical secretions
(Table 2). An example of a decrease in cervical IgA
band number and intensity is shown in Figure 2A
(lanes and 2). This patient also had a decrease in
cervical IgG in the third-trimester sample (Fig. 2B,
lanes and 2).
Postpartum Cervical HSV-2 IgA
Of the 14 HSV-2 seropositive women, 9 had speci-
mens taken at 6 weeks postpartum. Three speci-
mens were not used for comparison of antibody
profiles because they contained blood. Five of the
6 (83%) available pairs showed clear increases in
IgA complexity and intensity in the postpartum
samples and the sixth showed a decrease (Table
2). The patient in Figure 2A (lane 3) exemplifies
the dramatic changes in cervical IgA profiles post-
partum.
Overall, in 21 evaluable subjects with detectable
cervical IgA to HSV-1 or HSV-2, 43% had decreases
in apparent antibody levels between enrollment
and the third trimester; 24% had increases; and 33%
had no apparent change. Overall, 14 of 16 (88%)
HSV seropositive women had postpartum increases
in their cervical IgA to HSV (P 0.004 by 2-tailed
sign test).
Enrollment and Third-Trimester Cervical
HSV IgG
All 28 patients with paired specimens from enroll-
ment and third-trimester visits had detectable cervi-
cal anti-HSV IgG. Among the 14 with HSV-1 anti-
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Cervical Serum
IgA IgG IgA IgG
The IgA increased while the IgG showed no change
postpartum in 1 patient and the IgA increased while
the IgG decreased in patient. Four of 6 (67%)
available pairs had pronounced increases in cervical
IgG to HSV-2, while 2 (33%) had decreases. The
changes in cervical HSV-2 antibodies were concor-
dant between IgA and IgG in 5 of the 6 pairs; the
sixth had an increase in IgA and a decrease in IgG
postpartum. Overall, 12 patients (75%) had in-
creased cervical IgG to HSV postpartum, while 3
(19%) had decreases and (6%) had no change
(P 0.08 for proportion with increased postpartum
IgG by 2-tailed sign test).
A B C D
Fig. 2. Cervical and serum antibody profiles in samples
obtained over time from an HSV-2 seropositive patient.
ECL-Western blots were performed to detect cervical anti-
bodies to HSV-2 (.,1) and serum antibodies to HSV-2
(C,D). The left blot in each panel is from specimens taken
at enrollment, the middle blot from specimens taken during
the third trimester, and the right blot from specimens taken
6 weeks postpartum. Note the dramatic change in intensity
and number of bands in the cervical IgA profile of the post-
partum specimen compared with the cervical IgA profiles
from specimens taken during pregnancy. In contrast, the
cervical IgG and serum IgA and IgG profiles changed little
over time.
body, 7 had no change in IgG profiles, 3 had
increased intensity of their profiles, and 4 had de-
creased intensity of their profiles at the third trimes-
ter (Table 2). Ofthe 14 HSV-2 seropositive patients,
4 had no change in cervical IgG profiles, 6 had
increased intensity of reactive bands, and 4 had
decreased intensity of their profiles (Table 2). Over-
all, of the 28 patients, 39% had no change in cervical
IgG, 32% had increased apparent levels of cervical
IgG, and 29% had decreased intensity of bands at
the third trimester.
Serum Antibody Profiles Pre- and Postpartum
Sera were drawn at all 3 visits from 6 HSV-1 and 6
HSV-2 seropositive women. Serum IgA and IgG
profiles were examined between enrollment and
the third-trimester and postpartum visits. Among
the 6 women with HSV-1 antibodies, 3 had no de-
tectable changes, 2 had IgA (but not IgG) profiles
that decreased in complexity in the third trimester
and recovered to enrollment levels postpartum, and
a third had IgG (but not IgA) levels that dropped
at the third trimester but recovered postpartum. In
this latter patient, the cervical IgG changes roughly
paralleled those of serum IgG (Fig. 1B vs. Fig. 1D),
while the cervical IgA changed markedly without
a concomitant change in serum IgA profiles (Fig.
1A vs. Fig. 1C). Of the 6 who were HSV-2 seroposi-
tive, 3 had no detectable changes, had a rise in
serum IgA (but not IgG) at the third trimester,
had a decrease in both serum IgA and IgG at the
third trimester (changes which were reflected in
similar changes in cervical antibody), and had a
possible rise in serum IgA in the postpartum sample
(Fig. 2C). Overall, of the 12 women with sequential
serum samples, the changes in apparent levels of
serum HSV-specific IgA and IgG over time were
either not detected or were minor compared with
the profile changes seen over time with cervical
HSV-specific IgA and IgG.
Postpartum Cervical HSV IgG
Eight of 10 (80%) pairs of specimens from HSV-1
seropositive women showed pronounced increases
in cervical IgG to HSV-1 in the postpartum samples
(Table 2). Figure 1B (lane 3) shows a modest in-
crease in cervical IgG postpartum. In 8 patients,
the IgG changes were concordant with IgA changes.
DISCUSSION
This pilot study indicates that there are fluctuations
in HSV-specific antibodies in cervical secretions
that are not seen in serum. Although serum anti-
body profiles changed little between pregnancy and
the postpartum visits, the total protein, total IgA,
and HSV-specific antibody levels in the cervix in-
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creased postpartum. The increasing intensity and
complexity of cervical HSV antibody profiles, both
IgA and IgG, at the postpartum visit are striking.
It is tempting to assume that these relatively low
levels ofcervical antibodies late in pregnancy reflect
broader immune suppression, which may account
for the previously reported increased rate ofpositive
genital herpes cultures during the third trimester.1
However, a study of more women earlier in preg-
nancy and for a longer period postpartum is neces-
sary to evaluate whether the increasing levels seen
postpartum are the normal levels or whether they
are transient evaluations. In previous studies ofnon-
pregnant women with either first-episode or recur-
rent genital HSV infections, the cultures were not
positive when the cervical IgA antibody level was
->1:2.17 In addition, the mean duration of genital
shedding ofHSV with both first-episode and recur-
rent outbreaks was 3 days shorter among women
who developed secretory IgA compared with those
without IgA. 17 These and more recent studies
19 are
suggestive that IgA may play a role in limiting the
duration of HSV shedding. However, since only
patient had a positive culture at any visit in our
study, only concurrent, more frequent sampling for
both virus and antibody in the cervix could address
this question.
The lack of change in serum IgG and IgA anti-
body levels over the course of pregnancy and the
postpartum visit is consistent with previous studies
of antibody levels in pregnant women,z The serum
antibody patterns do not account for the observed
changes in cervical antibody levels. Although no
changes were seen in the cervical levels of total
protein, IgG, or IgA between the enrollment and
third-trimester sampling points, the enrollment visit
occurred anytime before 20 weeks gestation. The
changes related to pregnancy may occur early in
pregnancy, but our sampling protocol did not in-
clude first-trimester visits in all cases. One im-
portant finding ofour study was the clear increase in
total cervical IgA levels between the third-trimester
and postpartum sampling. However, the total cervi-
cal IgG levels did not change significantly from the
third-trimester to the postpartum sampling.
It is not clear why the increase in cervical total
IgA and HSV-specific IgA was only 2-fold in HSV-
2 positive patients compared with 6-fold in HSV-1
only or HSV antibody negative women. It did not
appear to be related to the sampling technique.
The volume as measured in each sample was similar
at all 3 time points and in all 3 serologic groups,
but only a small number of women were studied.
Differences in HSV reactivation in the genital tract
may be a factor influencing this observation. Our
test method could not detect antibodies that were
complexed with antigen. Any apparent changes in
HSV-2 cervical antibodies may be affected by viral
shedding. More detailed study of changes in cervi-
cal antibodies during and after pregnancy among
women with genital HSV-1 infections would help
to elucidate whether the specific type of HSV in-
fecting the genital area has an effect on local anti-
body levels during and after pregnancy. Such stud-
ies will require more patients, more frequent
sampling, and more quantitative testing methods.
The differences in local antibodies seen during
pregnancy compared with postpartum values may
be related to the hormone changes of pregnancy.
Of interest, the serum antibody levels in pregnant
women do not show significant changes during
pregnancy compared with postpartum. In a study
of secretory component production by uterine tis-
sues in ovariectomized rats, progesterone was found
to cause a marked decrease in the production of
secretory component,
z5 This effect, which was dose
dependent, occurred whether or not the animals
were pretreated with estradiol. The high levels of
progesterone present during pregnancy may inhibit
the production of secretory component which
would then limit the local IgA antibody levels.
These factors could be further evaluated by more
frequent sampling of cervical IgA levels throughout
pregnancy and pairing them with progesterone lev-
els since the concentration of progesterone in-
creases markedly over the course of pregnancy. If
progesterone specifically affects secretory compo-
nent and not overall immunoglobulin production,
it would account for differences in local antibodies
without concomitant changes in serum antibody
levels.
For the evaluation of the changes in local immu-
nity suggested by this pilot study, a more compre-
hensive and detailed study is required. Comparing
a control group of nonpregnant women sampled at
similar intervals with a group of women before,
during, and after pregnancy would allow an evalua-
tion ofthe changes over time not related specifically
to pregnancy. More frequent sampling for both local
antibody levels and HSV reactivation detected by
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culture and polymerase chain reaction should be
included to assess the relationship between local
immunity and HSV shedding. In addition, a mea-
surement of antibody levels to an antigen not pres-
ent in the genital tract such as tetanus would allow
a delineation of the changes in levels related to
antigenic stimulation compared with nonspecific
immune-system activation or changes related to
pregnancy. The development of more precise
methods for collection and quantitation of HSV-
specific antibody levels in cervical secr6tions rather
than just a comparison of changes in intensity and
complexity of Western blot patterns is necessary
to evaluate potential pregnancy-related changes in
local antibody. Furthermore, since Western blots
measure antibody levels to denatured proteins
rather than the intact virion, a correlation of anti-
body levels with neutralizing activity, viral shed-
ding, and cellular immune responses in the genital
tract is necessary to evaluate the clinical significance
of changes in ECL-Western blot antibody re-
sponses over time.
The methods used in our study could be adapted
for a study of the mucosal immune responses to
other antigens as well. An evaluation of genital im-
munity, including antibody response, will be crucial
in evaluating the response to human immunodefi-
ciency virus, especially to vaccines designed to pro-
tect against human immunodeficiency virus in-
fection.
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